O
OrbiMed Portfolio holdings
AUM
$3.98B
This Quarter Return
-3.5%
1 Year Return
+13.05%
3 Year Return
+159.74%
5 Year Return
+207.27%
10 Year Return
+1,027.33%
AUM
$4.82B
AUM Growth
+$4.82B
(-12%)
Cap. Flow
-$176M
Cap. Flow
% of AUM
-3.65%
Top 10 Holdings %
Top 10 Hldgs %
44.7%
Holding
132
New
19
Increased
23
Reduced
22
Closed
17
Top Buys
| 1 |
UPB
Upstream Bio, Inc. Common Stock
UPB
|
$93.6M |
| 2 |
Neurocrine Biosciences
NBIX
|
$86.8M |
| 3 |
Edwards Lifesciences
EW
|
$84.8M |
| 4 |
Alnylam Pharmaceuticals
ALNY
|
$38.9M |
| 5 |
Cytokinetics
CYTK
|
$38.4M |
Top Sells
| 1 |
Amgen
AMGN
|
$81.3M |
| 2 |
Elevance Health
ELV
|
$55.2M |
| 3 |
Merck
MRK
|
$48.4M |
| 4 |
Regeneron Pharmaceuticals
REGN
|
$47.5M |
| 5 |
Evolent Health
EVH
|
$47.1M |
Sector Composition
| 1 | Healthcare | 98.94% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
51
Amicus Therapeutics
FOLD
$2.34B
| $21.5M | 0.44% | 2,285,400 +1,715,100 | +301% | +$16.2M |
|
52
scPharmaceuticals
SCPH
$295M
| $21.5M | 0.44% | 6,059,528 | – | – |
|
53
RAPT Therapeutics
RAPT
$188M
| $20.8M | 0.43% | +13,135,260 | New | +$20.8M |
|
54
Tyra Biosciences
TYRA
$675M
| $20.4M | 0.42% | 1,470,086 +701,448 | +91% | +$9.75M |
|
55
Mineralys Therapeutics
MLYS
$1.03B
| $19.8M | 0.41% | 1,611,637 -391,302 | -20% | -$4.82M |
|
56
Structure Therapeutics
GPCR
$1.11B
| $17.7M | 0.36% | 652,028 +268,323 | +70% | +$7.28M |
|
57
Keros Therapeutics
KROS
$618M
| $16.1M | 0.33% | 1,018,734 | – | – |
|
58
C4 Therapeutics
CCCC
$185M
| $15.8M | 0.32% | 4,377,900 | – | – |
|
59
Medpace
MEDP
$13.4B
| $14.9M | 0.31% | 44,900 | – | – |
|
60
Verastem
VSTM
$569M
| $14.8M | 0.3% | 2,862,448 | – | – |
|
61
Prelude Therapeutics
PRLD
$68.5M
| $13.9M | 0.29% | 10,909,256 | – | – |
|
62
Corbus Pharmaceuticals
CRBP
$115M
| $13.8M | 0.28% | 1,172,287 +259,735 | +28% | +$3.06M |
|
63
Forte Biosciences
FBRX
$137M
| $13.6M | 0.28% | +600,000 | New | +$13.6M |
|
|
ITCI
64
DELISTED
Intra-Cellular Therapies Inc.
ITCI
| $13.6M | 0.28% | +163,000 | New | +$13.6M |
|
|
SLRN
65
DELISTED
ACELYRIN
SLRN
| $12.6M | 0.26% | 4,001,711 | – | – |
|
66
AbCellera Biologics
ABCL
$1.25B
| $12.2M | 0.25% | 4,180,768 | – | – |
|
67
ADC Therapeutics
ADCT
$345M
| $11.9M | 0.24% | 5,968,451 +1,434,650 | +32% | +$2.85M |
|
68
Adicet Bio
ACET
$59.9M
| $11M | 0.23% | 11,447,140 | – | – |
|
69
PMV Pharmaceuticals
PMVP
$74.2M
| $9.78M | 0.2% | 6,475,291 | – | – |
|
70
Neumora Therapeutics
NMRA
$280M
| $8.53M | 0.18% | 804,996 -695,004 | -46% | -$7.37M |
|
71
Q32 Bio
QTTB
$20.9M
| $7.75M | 0.16% | 2,252,987 | – | – |
|
72
Geron
GERN
$893M
| $7.67M | 0.16% | +2,168,000 | New | +$7.67M |
|
73
Avalo Therapeutics
AVTX
$122M
| $7.18M | 0.15% | 967,000 | – | – |
|
74
Cardiff Oncology
CRDF
$140M
| $6.68M | 0.14% | +1,538,462 | New | +$6.68M |
|
75
Scholar Rock
SRRK
$3.14B
| $6.56M | 0.14% | 151,800 -590,500 | -80% | -$25.5M |
|